Liposome structures and methods of use thereof
The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide.
1. A liposome comprising non-pore forming pHLIP polypeptide monomers covalently attached to polar headgroups of phospholipids in the lipid bilayer of said liposome, wherein the hydrophobic phospholipid tail region of the lipid bilayer of said liposome is substantially free of said pHLIP polypeptide monomers, wherein said liposome further comprises a hydrophobic or non-polar cargo incorporated into said lipid bilayer, and wherein said cargo comprises a therapeutic agent or a diagnostic agent.
2. The liposome of claim 1 , wherein the pHLIP polypeptide monomers are directly attached to polar headgroups of phospholipids in the lipid bilayer.
3. The liposome of claim 1 , wherein the cargo is non-polar.
4. The liposome of claim 1 , wherein the cargo comprises a gene regulation agent.
5. The liposome of claim 1 , wherein the cargo comprises a therapeutic agent.
6. The liposome of claim 5 , wherein the therapeutic agent comprises a chemotherapeutic or anti-tumor compound.
7. The liposome of claim 6 , wherein the chemotherapeutic compound comprises paclitaxel.
8. The liposome of claim 6 , wherein the chemotherapeutic compound comprises ceramide.
9. The liposome of claim 6 , wherein the chemotherapeutic compound comprises doxorubicin.
10. The liposome of claim 1 , wherein the cargo comprises a diagnostic agent.
11. The liposome of claim 10 , wherein the diagnostic agent comprises an imaging agent.
12. The liposome of claim 11 , wherein the imaging agent comprises a fluorescent imaging agent.
13. The liposome of claim 12 , wherein the fluorescent imaging agent comprises a fluorescent dye.
14. The liposome of claim 12 , wherein the fluorescent imaging agent comprises rhodamine or fluorescein.
15. The liposome of claim 14 , wherein the rhodamine forms part of a rhodamine-fatty acid.
16. The liposome of claim 1 , wherein
(a) the amino-terminal ends of the pHLIP polypeptide monomers are covalently attached to the polar headgroups, or
(b) the carboxy-terminal ends of the pHLIP polypeptide monomers are covalently attached to the polar headgroups.
17. The liposome of claim 1 , wherein the lipid bilayer comprises polyethylene glycol (PEG)-phospholipids.
18. The liposome of claim 1 , wherein each of the pHLIP polypeptide monomers comprises 13 to 25 amino acids, and the 13 to 25 amino acids comprise at least 6 non-polar amino acids, and at least 1 protonatable amino acid.
19. A method of delivering a cargo into a target cell comprising contacting said target cell with cargo-loaded pHLIP + liposomes according to claim 1 , wherein at least 10% more of said cargo is delivered to said target cell compared to the amount delivered using pHLIP − liposomes.
20. The method of claim 19 , wherein said target cell is characterized by a microenvironment comprising a low pH.
21. The method of claim 20 , wherein said target cell is a tumor cell, ischemic cell, inflamed cell, bacterially-infected cell, fungus-infected cells, or virally-infected cell.
22. A pharmaceutical composition comprising the liposome of claim 1 .
23. A liposome comprising polymer-phospholipids in the lipid bilayer thereof, wherein non-pore forming pHLIP polypeptide monomers are covalently attached to the polymer-phospholipids, wherein the hydrophobic phospholipid tail region of the lipid bilayer of said liposome is substantially free of said pHLIP polypeptide monomers, wherein said liposome further comprises a hydrophobic or non-polar cargo incorporated into said lipid bilayer, and wherein said cargo comprises a therapeutic agent or a diagnostic agent.
24. The liposome of claim 23 , wherein the polymer-phospholipids comprise polyethylene glycol (PEG)-phospholipids.